Wuxi STA Begins Operations of First Continuous Manufacturing Line for Oral Solids

Pharma Technology Wuxi STA Begins Operations of First Continuous Manufacturing Line for Oral Solids

2023-01-10 Source: Press release Wuxi STA 1 min Reading Time

Related Vendors

DeFacto | Leading Strategies

Turck_Your_Global_Automation_Partner.jpg ()

TURCK GmbH

Elementar Analysensysteme GmbH

Anton Paar GmbH

Wuxi STA has launched its first continuous manufacturing line for oral solids at its drug production site in Wuxi city, China. The continuous manufacturing line is equipped with the process analytical technology which helps to monitor blending uniformity, allowing for real-time analysis and control during production.

The new CM line provides global customers an enhanced oral drug development solution, enabling higher yields and shortened timelines to market.(Source: Wuxi STA) — The new CM line provides global customers an enhanced oral drug development solution, enabling higher yields and shortened timelines to market.
(Source: Wuxi STA)

Shanghai/China – Wuxi STA, a subsidiary of Wuxi Apptec, has recently announced that its first drug product Continuous Manufacturing (CM) line for oral solids is in operation at the drug product site located in Wuxi city, China. This new CM line provides global customers an enhanced oral drug development solution, enabling higher yields and shortened timelines to market.

Wuxi STA’s continuous manufacturing line features continuous direct compression equipment with unit operations including dispensing, blending, lubrication, tablet compression, and coating. The equipment design complies with the global cGMP regulations. Process Analytical Technology (Pat) is implemented within the CM line to monitor blending uniformity, allowing for real-time analysis and control during production to ensure high product quality.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

Wuxi STA’s drug product facilities across North America, Europe, and Asia have been inspected by major regulatory agencies including US FDA, EMA, China NMPA, Swissmedic, Japan PMDA, and South Korea MFDS to support global customers with clinical and commercial drug product manufacturing services. The Wuxi city site, where this new CM line was launched, is an integrated formulation development and manufacturing campus with comprehensive analytical platform for both oral and injectable formulations.

(ID:48983693)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.